Grant name: Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
Funding organization: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Total funding amount: Up to $500,000 per year for UG3 phase
Duration: UG3 phase up to 2 years, UH3 phase up to 3 additional years
Primary objective: Accelerate the development of devices to treat Substance Use Disorders (SUDs)
Significance: Addresses the substantial public health need for new SUD interventions
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized and Other)
Federal Government Agencies
U.S. Territories or Possessions
Independent School Districts
Public Housing Authorities/Indian Housing Authorities
Faith-based or Community-based Organizations
Regional Organizations
Foreign Organizations
Development of neuromodulatory or neurophysiological devices for SUDs
Encouragement of testing device-based interventions previously approved for other indications
Research on the mechanism of action of devices
Applicants must demonstrate expertise in device development and testing
Involvement of regulatory authorities (FDA) in the development plan
Application budgets limited to $500,000 direct costs for each year of the UG3 phase
No limit on budget for the UH3 phase, but must reflect actual project needs
Open Date: July 14, 2025
Application Due Dates: December 18, 2025 and August 13, 2026
Earliest Start Date: August 13, 2025
Must comply with NIH Grants Policy Statement and federal regulations
Investigational Device Exemption (IDE) requirements must be addressed
Applications must be submitted electronically via Grants.gov
Compliance with application instructions is strictly enforced